Amplia Therapeutics (ASX:ATX)
ASX announcement history & article coverage
Transparent by design.
Announcments by Amplia Therapeutics (ASX:ATX) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Amplia Receives R&D Tax Rebate Totalling $4.78 Million
Amplia receives A$4.78 million R&D tax rebate to fund cancer drug trials
Amplia Therapeutics Provides Clinical Trial Updates
Response to ASX Price Query
Amplia denies undisclosed information behind sharp share price move
Amplia Presents at CG Drug and Device Conference 2026
Amplia Presents at E&P Healthcare Conference 2026
Amplia and ANZGOG Finalise Protocol for Ovarian Cancer Trial
Notification regarding unquoted securities - ATX
Results of Annual General Meeting
CEO Managing Director Presentation to Annual General Meeting
Bioshares Biotech Summit Presentation
Amplia signs Collaboration and Supply Agreement with Lilly
Amplia and Lilly collaborate on clinical trial combining narmafotinib and olomorasib for NSCLC
Scientific Paper Studies of narmafotinib - Pancreatic Cancer
Quarterly Activities/Appendix 4C Cash Flow Report
Amplia Therapeutics advances narmafotinib trials, board renewal, and IP expansion with A$24M cash
Notice of Annual General Meeting/Proxy Form